Revlimid revenue cliff
Generic Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.
CIPLA / Q2-FY26 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Execution risk on US pipeline launches
Delays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.
India branded business growth slowdown
India branded business grew only 7% YoY, below the market, due to weak acute season and team restructuring.
Tirzepatide exclusivity and competition
Potential competition from semaglutide generics and uncertainty over exclusivity terms with Lilly could limit tirzepatide upside.